CERo Therapeutics (CERO) Competitors

Unity Biotechnology (NASDAQ:UBX) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Which has better valuation and earnings, UBX or CERO?

CERo Therapeutics has lower revenue, but higher earnings than Unity Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unity Biotechnology	$240K	57.23	-$39.86M	-$1.62	-0.49
CERo Therapeutics	N/A	N/A	-$2.54M	N/A	N/A

Does the MarketBeat Community favor UBX or CERO?

Unity Biotechnology received 179 more outperform votes than CERo Therapeutics when rated by MarketBeat users. Likewise, 66.91% of users gave Unity Biotechnology an outperform vote while only 50.00% of users gave CERo Therapeutics an outperform vote.

Company	Underperform	Outperform
Unity Biotechnology	Outperform Votes 182 66.91%	Underperform Votes 90 33.09%
CERo Therapeutics	Outperform Votes 3 50.00%	Underperform Votes 3 50.00%

Do institutionals and insiders believe in UBX or CERO?

29.5% of Unity Biotechnology shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 5.8% of Unity Biotechnology shares are owned by company insiders. Comparatively, 12.7% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility & risk, UBX or CERO?

Unity Biotechnology has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Does the media refer more to UBX or CERO?

In the previous week, CERo Therapeutics had 6 more articles in the media than Unity Biotechnology. MarketBeat recorded 7 mentions for CERo Therapeutics and 1 mentions for Unity Biotechnology. Unity Biotechnology's average media sentiment score of 1.89 beat CERo Therapeutics' score of 0.69 indicating that Unity Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Unity Biotechnology	Very Positive
CERo Therapeutics	Positive

Is UBX or CERO more profitable?

CERo Therapeutics' return on equity of 0.00% beat Unity Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unity Biotechnology	N/A	-119.70%	-45.86%
CERo Therapeutics	N/A	N/A	-108.43%

Do analysts rate UBX or CERO?

Unity Biotechnology currently has a consensus target price of $3.75, suggesting a potential upside of 369.92%. CERo Therapeutics has a consensus target price of $140.00, suggesting a potential upside of 1,815.18%. Given CERo Therapeutics' higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Unity Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unity Biotechnology	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
CERo Therapeutics	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Unity Biotechnology beats CERo Therapeutics on 8 of the 14 factors compared between the two stocks.